Inhibition of NF-κB activation by merlin

Biochemical and Biophysical Research Communications

Volumn 296, Issue 5, 2002, Pages 1295-1302

  Kim, Jae Young ^a   Kim, Hongtae ^a   Jeun, Sin Soo ^a   Rha, Suk Joo ^a   Kim, Young Hoon ^a   Ko, Young Jin ^a   Won, Jonghwa ^b   Lee, Kweon Haeng ^a   Rha, Hyoung Kyun ^a   Wang, Young Pil ^a  

^a The Catholic University of Korea   (South Korea)

^b Mogam Biotechnology Research Institute   (South Korea)

Author keywords

Neurofibromatosis type 2 (NF2); NF B; p65; TNF

Indexed keywords

AMINO ACID DERIVATIVE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MERLIN; MUTANT PROTEIN; PROTEIN NF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CHUK PROTEIN, MOUSE; DNA BINDING PROTEIN; I KAPPA B; I KAPPA B KINASE; IKBKB PROTEIN, MOUSE; IKBKE PROTEIN, MOUSE; NF KAPPA B KINASE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPA B KINASE; NF-KAPPAB INHIBITOR ALPHA; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR RELA;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DRUG EFFICACY; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; REPORTER GENE; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CELL STRAIN 3T3; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; RAT; TRANSACTIVATION;

FALCO COLUMBARIUS;

3T3 CELLS; ANIMALS; DNA-BINDING PROTEINS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MICE; NEUROFIBROMIN 2; NF-KAPPA B; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RATS; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR RELA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035984336     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02077-6     Document Type: Article

References (35)

1. R.L. Martuza, R. Eldridge, Neurofibromatosis 2 (bilateral acoustic neurofibromatosis), N. Engl. J. Med. 318 (1998) 684-688.
2. J.F. Gusella, V. Ramesh, M. MacCollin, L.B. Jacoby, Neurofibromatosis 2: loss of merlin's protective spell, Curr. Opin. Genet. Dev. 6 (1996) 87-92.
3. G.A. Rouleau, P. Merel, M. Lutchman, M. Sanson, J. Zucman, C. Marineau, K. Hoang-Xuan, S. Demczuk, C. Desmaze, B. Plougastel, Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2, Nature 363 (1993) 515-521.
4. J.A. Trofatter, M.M. MacCollin, J.L. Rutter, J.R. Murrell, M.P. Duyao, D.M. Parry, R. Eldridge, N. Kley, A.G. Menon, K. Pulaski, A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor, Cell 72 (1993) 791-800.
5. K. Ikeda, Y. Saeki, C. Gonzalez-Agosti, V. Ramesh, E.A. Chiocca, Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer, J. Neurosurg. 91 (1999) 85-92.
6. H. Morrison, L.S. Sherman, J. Legg, F. Banine, C. Isacke, C.A. Haipek, D.H. Gutmann, H. Ponta, P. Herrlich, The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44, Genes Dev. 15 (2001) 968-980.
7. L. Sherman, H.M. Xu, R.T. Geist, S. Saporito-Irwin, N. Howells, H. Ponta, P. Herrlich, D.H. Gutmann, Interdomain binding mediates tumor growth suppression by the NF2 gene product, Oncogene 15 (1997) 2505-2509.
8. M. Giovannini, E. Robanus-Maandag, M. van der Valk, M. Niwa-Kawakita, V. Abramowski, L. Goutebroze, J.M. Woodruff, A. Berns, G. Thomas, Conditional biallelic NF2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2, Genes Dev. 14 (1997) 1617-1630.
9. A.I. McClatchey, I. Saotome, K. Mercer, D. Crowley, J.F. Gusella, R.T. Bronson, T. Jacks, Mice heterozygous for a mutation at the NF2 tumor suppressor locus develop a range of highly metastatic tumors, Genes Dev. 12 (1998) 1121-1133.
10. A. Tikoo, M. Varga, V. Ramesh, J. Gusella, H. Maruta, An antiras function of neurofibromatosis type 2 gene product (NF2/Merlin), J. Biol. Chem. 269 (1994) 23387-23390.
11. R.J. Shaw, J.G. Paez, M. Curto, A. Yaktine, W.M. Pruitt, I. Saotome, J.P. O'Bryan, V. Gupta, N. Ratner, C.J. Der, T. Jacks, A.I. McClatchey, The NF2 tumor suppressor, merlin, functions in Rac-dependent signaling, Dev. Cell 1 (2001) 63-72.
12. P.A. Baeuerle, T. Henkel, Function and activation of NF-κB in the immune system, Annu. Rev. Immunol. 12 (1994) 141-179.
13. A.S. Baldwin Jr., The NF-κB and IκB proteins: new discoveries and insights, Annu. Rev. Immunol. 14 (1996) 649-683.
14. F. Mercurio, A.M. Manning, Multiple signals converging on NF-κB, Curr. Opin. Cell. Biol. 11 (1999) 226-232.
15. H.W. Sharma, R. Narayanan, The NF-κB transcription factor in oncogenesis, Anticancer Res. 16 (1996) 589-596.
16. V.R. Baichwal, P.A. Baeuerle, Activate NF-κB or die?, Curr. Biol. 7 (1997) 94-96.
17. M.W. Mayo, C.Y. Wang, P.C. Cogswell, K.S. Rogers-Graham, S.W. Lowe, C.J. Der, A.S. Baldwin Jr., Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras, Science 278 (1997) 1812-1815.
18. T.S. Finco, J.K. Westwick, J.L. Norris, A.A. Beg, C.J. Der, A.S. Baldwin Jr., Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation, J. Biol. Chem. 272 (1997) 24113-24116.
19. T.D. Gilmore, M. Koedood, K.A. Piffat, D.W. White, Rel/NF-κB/IκB proteins and cancer, Oncogene 13 (1996) 1367-1378.
20. B. Rayet, C. Gelinas, Aberrant Rel/NF-κB genes and activity in human cancer, Oncogene 18 (1999) 6938-6947.
21. E. Cabannes, G. Khan, F. Aillet, R.F. Jarrett, R.T. Hay, Mutations in the IκBα gene in Hodgkin's disease suggest a tumour suppressor role for IκBα, Oncogene 18 (1999) 3063-3070.
22. D. Krappmann, F. Emmerich, U. Kordes, E. Scharschmidt, B. Dorken, C. Scheidereit, Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells, Oncogene 18 (1999) 943-953.
23. Z.L. Chu, J.A. DiDonato, J. Hawiger, D.W. Ballard, The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates IκB kinases containing IKKα and IKKβ, J. Biol. Chem. 273 (1998) 15891-15894.
24. J.Y. Reuther, G.W. Reuther, D. Cortez, A.M. Pendergast, A.S. Baldwin Jr., A requirement for NF-κB activation in Bcr-Abl-mediated transformation, Genes Dev. 12 (1998) 968-981.
25. J.A. Gustin, T. Maehama, J.E. Dixon, D.B. Donner, The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor-κB activity, J. Biol. Chem. 276 (2001) 27740-27744.
26. G.A. Webster, N.D. Perkins, Transcriptional cross talk between NF-κB and p53, Mol. Cell. Biol. 19 (1999) 3485-3495.
27. M.M. Muller, E. Schreiber, W. Schaffner, P. Matthias, Rapid test for in vivo stability and DNA binding of mutated octamer binding proteins with 'mini-extracts' prepared from transfected cells, Nucleic Acids Res. 17 (1989) 6420.
28. K.M. Schulze, C.O. Hanemann, H.W. Muller, H. Hanenberg, Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis, Hum. Mol. Genet. 11 (2002) 69-76.
29. N.L. Malinin, M.P. Boldin, A.V. Kovalenko, D. Wallach, MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1, Nature 385 (1997) 540-544.
30. R. Gary, A. Bretscher, Heterotypic and homotypic associations between ezrin and moesin, two putative membrane-cytoskeletal linking proteins, Proc. Natl. Acad. Sci. USA 90 (1993) 10846-10850.
31. R. Gary, A. Bretscher, Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site, Mol. Biol. Cell. 6 (1995) 1061-1075.
32. M.D. Henry, C. Gonzalez Agosti, F. Solomon, Molecular dissection of radixin: distinct and interdependent functions of the amino- and carboxy-terminal domains, J. Cell. Biol. 129 (1995) 1007-1022.
33. D. Wang, A.S. Baldwin Jr., Activation of NF-κB-dependent transcription by tumor necrosis factor-α is mediated through phosphorylation of RelA/p65 on serine 529, J. Biol. Chem. 273 (1998) 29411-29416.
34. D. Wang, S.D. Westerheide, J.L. Hanson, A.S. Baldwin Jr., Tumor necrosis factor-α induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II, J. Biol. Chem. 275 (2000) 32592-32597.
35. H. Zhong, R. Voll, S. Ghosh, Phosphorylation of NF-kappaB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300, Mol. Cell. 1 (1998) 661-671.